Novavax announced start of rolling review by multiple regulatory authorities for COVID-19 vaccine authorization
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
On Feb. 4, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, had submitted an application to the…
On Feb. 3, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
On Feb. 3, 2021, XPhyto announced an agreement with Applied Pharmaceutical Innovation for the synthesis of pharmaceutical grade…
On Feb. 3, 2021, Vaxart announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its…
On Feb. 3, 2021, AXIM Biotechnologies announced initiation of clinical trials for ImmunoPass, the Companyメs rapid point-of-care test…
On Feb. 3, 2021, Quidel announced the opening of a new manufacturing facility in Carlsbad, CA that was…
On Feb. 3, 2021, Dynavax Technologies and Serum Institute of India announced that the first participant has been…
On Feb. 3, 2021, IAVI and Scripps Research announced a phase 1 clinical trial testing a novel vaccine…
On Feb. 3, 2021, Avid Bioservices and Humanigen announced that they had entered into a manufacturing services agreement…
On Feb. 3, 2021, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 7.5…
On Feb. 3, 2021, Moderna announced that the Singapore Health Sciences Authority (HSA) had approved the interim authorization…
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
On Feb. 3, 2021, an experimental single-dose, intranasal influenza vaccine, was safe and produced a durable immune response…
On Feb. 3, 2021, BD (Becton, Dickinson) announced the CE mark of BD Multitestル 6-Color TBNK Reagent with…
On Feb. 3, 2021, Bristol-Myers and The Rockefeller University announced an agreement under which Bristol Myers Squibb was…
On Feb. 3, 2021, RELIEF THERAPEUTICS affirmed that its collaboration partner NeuroRx had initiated a phase 2/3 clinical…
On Feb. 2, 2021, GlaxoSmithKline and CureVac announced a new タ150m collaboration, building on their existing relationship, to…
On Feb. 2, 2021, Mateon Therapeutics announced that its ARTI-19 trial, evaluating ARTIVeda / PulmoHeal against COVID-19 in…
On Feb. 2, 2021, Oragenics announced that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National…
On Feb. 2, 2021, VBI Vaccines announced that the FDA had accepted its filing of the Biologics License…
On Feb. 2, 2021, Novavax announced a memorandum of understanding (MOU) with the Canadian government to produce NVX-CoV2373,…
On Feb. 1, 2021, Roche announced it had obtained the CE mark for its new SARS-CoV-2 Rapid Antigen…
On Feb. 1, 2021, researchers at the National Institutes of Health and their collaborators found that inhaling unfragmented…
On Feb. 1, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced a plan to initiate a global Phase 2/3…
On Feb. 1, 2021, Dynavax Technologies and the Coalition for Epidemic Preparedness Innovations (CEPI) announced they have entered…
On Feb. 1, 2021, Dynavax Technologies announced Valneva had informed it that the UK Government exercised its option…
On Feb. 1, 2021, Pfizer and BioNTech announced that preclinical data in non-human primate and mouse models from…
On Jan. 31, 2021, Sorrento Therapeutics announced additional positive results from its Phase 1b study of human allogeneic…
On Jan. 30, 2021, as the COVID-19 pandemic continued to surge in the U.S., the CDC implemented a…